Summary by Futu AI
Intelligent Bio Solutions Inc., a Delaware-incorporated medical technology company, announced preliminary unaudited revenue results for the fiscal second quarter and six months ended December 31, 2023, on February 2, 2024. The company, which is listed on the Nasdaq Stock Market under the symbol INBS, reported a significant year-over-year revenue increase of 114% for the quarter and 337% for the six-month period. The company's Chief Financial Officer, Spiro Sakiris, expressed optimism about the growth, attributing it to market penetration efforts. Additionally, the company saw a 30% rise in cartridge sales and a 91% rise in reader sales. President and CEO Harry Simeonidis highlighted the company's expansion into New Zealand and anticipated growth in the Asia-Pacific region. The company's drug screening solution...Show More